Prednisone
- Generic Name
- Prednisone
- Brand Names
- Deltasone, Rayos, Winpred
- Drug Type
- Small Molecule
- Chemical Formula
- C21H26O5
- CAS Number
- 53-03-2
- Unique Ingredient Identifier
- VB0R961HZT
- Background
A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.
Prednisone was granted FDA approval on 21 February 1955.
- Indication
Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.
- Associated Conditions
- Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis
- Associated Therapies
- Palliative Treatment
Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2016-11-29
- Target Recruit Count
- 130
- Registration Number
- NCT00141037
- Locations
- 🇺🇸
UCLA - Department of Pediatrics, Division of Nephrology, Los Angeles, California, United States
🇺🇸Children's Hospital Boston - Division of Nephrology, Boston, Massachusetts, United States
🇺🇸Children's Hospital of New Orleans-Department of Pediatric Nephrology, New Orleans, Louisiana, United States
A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus
- Conditions
- Interventions
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2019-08-20
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 262
- Registration Number
- NCT00137969
- Locations
- 🇺🇸
Univ of Calif., Los Angeles; Rheumatology, Los Angeles, California, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Emory Uni ; Division of Rheumatology, Atlanta, Georgia, United States
Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2011-08-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 93
- Registration Number
- NCT00137436
- Locations
- 🇺🇸
Pfizer Investigational Site, Madison, Wisconsin, United States
A Study in Adults With Untreated Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 100
- Registration Number
- NCT00136435
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇨🇦Manitoba Blood & Marrow Transplant Program CancerCare Manitoba, Winnipeg, Manitoba, Canada
Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD)
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2022-01-31
- Lead Sponsor
- Mesoblast, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT00136903
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸St. Francis Hospital, Indianapolis, Indiana, United States
🇺🇸New York Medical College, Valhalla, New York, United States
Study of Bortezomib Combined With ACVBP in Peripheral T-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2018-08-23
- Lead Sponsor
- Lymphoma Study Association
- Target Recruit Count
- 60
- Registration Number
- NCT00136565
- Locations
- 🇧🇪
Groupe d'Etude des Lymphomes de l'Adulte, Yvoir, Belgium
🇫🇷Service d'Hématologie - Centre Hospitalier Lyon-Sud, Pierre-Bénite cedex, France
🇫🇷Centre Hospitalier Robert Debré, Reims, France
R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2005-08-26
- Last Posted Date
- 2018-08-23
- Lead Sponsor
- Lymphoma Study Association
- Target Recruit Count
- 138
- Registration Number
- NCT00135499
- Locations
- 🇫🇷
Centre Hospitalier Robert Debré, Reims, France
🇨🇭Schweirische Arbeitsgruppe fur klinische Krebsforschung, Lausanne, Switzerland
🇧🇪Groupe d'Etude des Lymphomes de l'adulte, Yvoir, Belgium
S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy
- Conditions
- Interventions
- First Posted Date
- 2005-08-24
- Last Posted Date
- 2021-10-27
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 1038
- Registration Number
- NCT00134056
- Locations
- 🇺🇸
Saint Joseph's Hospital of Atlanta, Atlanta, Georgia, United States
🇺🇸Northside Hospital Cancer Center, Atlanta, Georgia, United States
🇺🇸CCOP - Atlanta Regional, Atlanta, Georgia, United States
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia
- First Posted Date
- 2005-08-24
- Last Posted Date
- 2018-09-17
- Target Recruit Count
- 23
- Registration Number
- NCT00133991
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Drexel University College of Medicine - Center City Hahnemann Campus, Philadelphia, Pennsylvania, United States
Effect of Rapid Steroid Withdrawal on Subclinical Markers of Rejection
- Conditions
- Interventions
- First Posted Date
- 2005-08-23
- Last Posted Date
- 2014-09-08
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 85
- Registration Number
- NCT00133172
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.